López ME

Language: Spanish
References: 14
Page: 509-514
PDF size: 57.01 Kb.

ABSTRACT

Pulmonary arterial hypertension is a condition frequently observed or associated to many cardiovascular diseases and can become a severe complication in the postoperative period. In fact it can be present in patients with previous abnormal pulmonary presion or yet in patients with normal pulmonary presion in the preoperative period. Postoperative pulmonary arterial hypertension is an important condition because it may have a great number of associated complications like right ventricular failure and systemic hipotension. The presence of pulmonary hypertension during the postoperative period can compromise right ventricular function, left ventricular filling, left ventricular pressure and hence global perfusion. In the treatment of this group of patients a correct anestesic and surgical practice is of capital importance. In recent years the administration of many drugs for the control of the pulmonary presion has been useful for the treatment of this condition. In this paper we review the phisiopatologic mechanism involved in the disease, the consequences in the postoperative period and the drugs used in the treatment.

REFERENCES

1. López Mora E: Tratamiento de la hipertensión arterial postoperatoria. Arch Cardiol Mex 2002; 72, Suppl 1: S122-S125.

2. Blaise G, Langleben D, Hubert B: Pulmonary Arterial Hypertension. Anesthesiology 2003; 99: 1415-32.

3. Pamboukian S, Carere R, Webb J, Cook R, Dyanckova B, Abel J: The use of milrinone in pretransplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transpl 1999; 18: 367-71.

4. Stobierska B, Awad H, Michler R: The evolving managment of acute right sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923-31.

5. Tritapepe L, Voci P, Cogliati AA, Pasotti E, Papalia U, Minechetti A: A successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med 1999; 27: 2180-3.

6. Liaudet L, García SF, Szabo C: Biology of nitric oxide signaling. New Horizons 2000; 28: 37-54.

7. Dincer E, Presberg K: Current management of pulmonary hypertension. Clin Pulm Med 2004; 11: 40-53.

8. Hart M: Nitric oxide in adult lung disease. Chest 1999; 115: 1407-17.

9. Hayward CH, Kelly R, Macdonald P: Inhaled nitric oxide in cardiology practice. Cardiovasc Res 1999; 43: 628-38.

10. Balzer D, Kort H, Day R, Corneli H, Kovalchin J, Cannon B, et al: Inhaled nitric oxide as preoperative test (INOP test I).The INOP test study group. Circulation 2002; 106 suppl I: I-76-I-81.

11. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.

12. Haraldsson A, Kieler-Jensen N, Ricksten S: The additive pulmonary vasodilatory effects of inhaled prostaciclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-45.

13. Rex S, Busch T, Vettelschoss M, Derossi L, Rossaint R, Buhre W: Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology 2003; 99: 745-7.

14. Lowson S, Doctor A, Walsh B, Doorley P: Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 2002; 30: 2762-64.